Current Medication Practices and Preferences Among Patients With Psoriatic Arthritis.

ABSTRACT:

Objective

The aim of this study was to evaluate real-world psoriatic arthritis (PsA) medication use and patient medication preferences.

Methods

This is a cross-sectional survey of Classification for Psoriatic Arthritis criteria defined PsA patients recruited from a single-center PsA registry from June to September 2020. Preferences were ranked on a 5-point Likert scale ranging from "not at all important" to "extremely important."

Results

One hundred thirty-seven patients (29%) responded. The median duration (years) of PsA skin and joint symptoms was 19 (interquartile range, 10-34) and 12 (interquartile range, 8-21), respectively. The most common initial immunomodulatory medications were anti-tumor necrosis factor α (35%), methotrexate (19%), and anti-phosphodiesterase

SUBMITTER: Schwartzman M 

PROVIDER: S-EPMC8887780 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature